Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients | Zendy

Sunil V. Badve | Zendy; Elaine M. Pascoe | Zendy; Michael Burke | Zendy; Philip A. Clayton | Zendy; Scott B. Campbell | Zendy; Carmel M. Hawley | Zendy; Wai H. Lim | Zendy; Stephen P. McDonald | Zendy; Germaine Wong | Zendy; David W. Johnson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients

Author(s) -

Sunil V. Badve,

Elaine M. Pascoe,

Michael Burke,

Philip A. Clayton,

Scott B. Campbell,

Carmel M. Hawley,

Wai H. Lim,

Stephen P. McDonald,

Germaine Wong,

David W. Johnson

Publication year - 2016

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.00190116

Subject(s) - medicine , hazard ratio , confidence interval , proportional hazards model , sirolimus , kidney transplantation , cohort , cohort study , transplantation , oncology

Emerging evidence from recently published observational studies and an individual patient data meta-analysis shows that mammalian target of rapamycin inhibitor use in kidney transplantation is associated with increased mortality. Therefore, all-cause mortality and allograft loss were compared between use and nonuse of mammalian target of rapamycin inhibitors in patients from Australia and New Zealand, where mammalian target of rapamycin inhibitor use has been greater because of heightened skin cancer risk.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research